Skip to main content
Fig. 1 | BMC Dermatology

Fig. 1

From: Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial

Fig. 1

Patient disposition. Note that the 714 subjects includes subjects with mild, moderate, and severe psoriasis; subjects randomized are those that met the mild to moderate psoriasis eligibility criteria. Following database release, it was discovered that five subjects were randomized, but did not have any record of study drug dosing and were assessed in the clinical database as non-treated subjects; as a consequence, these subjects were excluded from all analyses. BID twice daily, QD once daily

Back to article page

BMC Dermatology

ISSN: 1471-5945

Contact us